BioSpace News Archive

According to Report, the global Stethoscope market size is expected to be worth around US$ 950 million by 2030 from valued at US$ 500.7 million in 2020 and is anticipated to grow at a CAGR of 11.3% during forecast period 2022 to 2030.

A recent report provides crucial insights along with application based and forecast information in the Global Sivelestat Sodium Market.

A recent report provides crucial insights along with application based and forecast information in the Global Dent Disease Treatment Market.

MedX Health Corp. (“ MedX ” or the “ Company ”) ( TSXV: MDX ), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.

CosmosID® today announced a partnership for long-term support for Locus’ clinical trial initiatives.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced several leadership changes as the company expands its clinical development and pipeline programs.

Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine has granted conditional approval of VETMEDIN®-CA1, which is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease, a form of chronic valvular heart disease in dogs.

Invetech launches Korus™, a closed system for autologous cell therapies that features elutriation and cell wash using gentle counterflow centrifugation.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, has been increasing its engagement with all stakeholders in anticipation of the June 21, 2022, effective date of the “rebuttable presumption” standard under the Uyghur Forced Labor Prevention Act (UFLPA) signed into law on December 23, 2021.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of units (the “Units”) at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the “Offering”).